7 completed, 2 terminated. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 6, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow AVE 5026: new trials by email Literature Review of AVE 5026 trials Research Report on AVE 5026
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line Semuloparin sodium - Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL) | Phase 2 | Terminated | Sanofi | 2 | 2012-05-01 | 2016-05-03 |
| Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery Enoxaparin sodium, Semuloparin sodium, Placebo - Venous Thromboembolism | Phase 3 | Completed | Sanofi | 1003 | 2008-07-01 | 2013-01-23 |
| Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility Semuloparin sodium, Enoxaparin sodium - Venous Thromboembolism | Phase 3 | Terminated | Sanofi | 421 | 2008-07-01 | 2013-01-23 |
| Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery Semuloparin sodium, Enoxaparin, Placebo - Venous Thromboembolism | Phase 3 | Completed | Sanofi | 1150 | 2008-07-01 | 2013-01-23 |
| Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium - Venous Thromboembolism | Phase 3 | Completed | Sanofi | 469 | 2008-06-01 | 2013-06-14 |
| Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery Semuloparin sodium, Enoxaparin sodium, Placebo - Venous Thromboembolism | Phase 3 | Completed | Sanofi | 2326 | 2008-06-01 | 2013-01-23 |
| Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy Semuloparin sodium, Placebo (for semuloparin) - Venous Thromboembolism, Cancer | Phase 3 | Completed | Sanofi | 3212 | 2008-06-01 | 2013-01-23 |
| Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery Semuloparin Sodium, Enoxaparin sodium, Placebo - Venous Thromboembolism | Phase 3 | Completed | Sanofi | 4413 | 2008-04-01 | 2013-12-16 |
| Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery Semuloparin sodium, Placebo (for Enoxaparin sodium), Enoxaparin sodium - Venous Thromboembolism | Phase 2 | Completed | Sanofi | 705 | 2006-05-01 | 2013-01-15 |
Venous Thromboembolism (8) · Venous Thrombosis (2) · Hip Fractures (1) · Neoplasms (1) · Thrombosis (1)
Sanofi (9)
Mexico (8) · Russia (8) · Canada (7) · Romania (7) · Ukraine (7) · United States (7) · Argentina (6) · Belarus (6) · Chile (6) · Colombia (6) · Czechia (6) · Denmark (6) · Greece (6) · India (6) · Poland (6)
Alexander Turpie, MD (3) · William D. Fisher, MD (2) · Ajay Kakkar, Prof., MD, PhD (1) · Alexander G. Turpie (1) · Alexander G. Turpie, MD (1) · Giancarlo Agnelli, MD (1) · Patrick Mismetti, MD (1)
PMID 22429800, PMID 19187076, PMID 22335737, PMID 23539696, PMID 24374549, PMID 33337539
2005 (1), 2008 (1)